Minerva-J&J's Amendment Of MIN-202 Contract Wins EU Approval
Zacks Investment Research | Aug 28, 2017 07:02AM ET
Minerva Neurosciences, Inc. (NASDAQ:NERV) announced that an amendment to its license agreement with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson (NYSE:JNJ) , related to co-development of orexin-2 receptor antagonist, MIN-202 (JNJ 42827922), has been approved of in the EU.
Notably, Minerva entered into the agreement with Janssen in June, the execution of which was dependent on the sanction of its certain term by the EU. Subsequently, each condition has now been met and the amendment is expected to take effect on Aug 29, 2017.
Pursuant to the agreement, Minerva is entitled to receive an upfront payment of $30 million from Janssen. Additionally, Minerva will also receive an amount of $20 million at the start of a phase III insomnia study for MIN-202 and $20 million upon 50% completion of enrollment in the study. Also, an amount of $13 million has been waived by Janssen that was due from Minerva for phase II development of the candidate.
Shares of Minerva have significantly underperformed the industry year to date. The stock has plunged 50.2% compared with the industry’s 2.2% decrease during the period.
We remind investors that in January 2016, the company announced positive top-line results from a phase IIa study of MIN-202 for the given indication. The trial was conducted on 28 patients with insomnia disorder.
Minerva’s other pipeline candidates include MIN-117, currently in clinical development for major depressive disorder (MDD), MIN-101 (three phase IIb study) for schizophrenia and MIN-301 for Parkinson’s disease.
Significantly in July, Minerva completed a public offering, having generated net proceeds of approximately $41.5 million. The company expects that this fund along with finances raised from the public stock offering and current financial resources, will together support five clinical studies projected to take place by 2019-end for other pipeline candidates including MIN-202.
Zacks Rank & Stocks to Consider
Minerva currently carries a Zacks Rank #2 (Buy). Some other stocks worth considering in the pharma sector are Aduro Biotech, Inc. (NASDAQ:ADRO) and ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) , both carrying a Zacks Rank #2. You can see .
Get The News You Want
Aduro Biotech’s loss per share estimates reduced from $1.46 to $1.32 for 2017 and from $1.41 to $1.24 over the last 30 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.
ACADIA’s loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7.97%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.